Assess the Effect of Metaxalone 640 mg (M640) Compared to Tizanidine 8 mg on Truck Driving Ability and Cognition
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Primus Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT06382662
- Locations
- ๐บ๐ธ
Sun Valley Arthritis Center, Peoria, Arizona, United States
Study to Assess Drowsiness, Cognition, Fall Risk After Metaxalone 640 mg and Metaxalone 800 mg
- Conditions
- Interventions
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Primus Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT06348303
- Locations
- ๐บ๐ธ
ClinOhio Research Institute, Columbus, Ohio, United States
Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Primus Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT06256575
Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions.
- Conditions
- Interventions
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Primus Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT06157177
- Locations
- ๐บ๐ธ
Jayashree Sinha, MD 1, Clovis, New Mexico, United States
๐บ๐ธEast Alabama Arthritis Center, Auburn, Alabama, United States
๐บ๐ธSean Wollaston, MD, Valley Village, California, United States
Vasculera in Participants With Lipedema
- First Posted Date
- 2022-11-15
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Primus Pharmaceuticals
- Target Recruit Count
- 34
- Registration Number
- NCT05616962
- Locations
- ๐บ๐ธ
Primus Pharmaceuticals, Scottsdale, Arizona, United States
EpiCeram for Skin Protection in Healthcare Workers
- First Posted Date
- 2021-03-11
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Primus Pharmaceuticals
- Target Recruit Count
- 1
- Registration Number
- NCT04793711
- Locations
- ๐บ๐ธ
Sun Valley Arthritis Center, Peoria, Arizona, United States
Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Primus Pharmaceuticals
- Target Recruit Count
- 22
- Registration Number
- NCT03179605
- Locations
- ๐บ๐ธ
Site 104, Madera, California, United States
๐บ๐ธSite 108, Santa Ana, California, United States
๐บ๐ธInvestigational Site 101, Lincoln, Nebraska, United States
Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2016-04-25
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Primus Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT02749799
- Locations
- ๐บ๐ธ
Site Four, Arlington Heights, Illinois, United States
๐บ๐ธSite Two, New Albany, Indiana, United States
๐บ๐ธSite Three, Las Vegas, Nevada, United States
Diosmiplex (Vasculeraยฎ) in Primary and Secondary Raynaud's Phenomenon
- Conditions
- Interventions
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- Primus Pharmaceuticals
- Target Recruit Count
- 87
- Registration Number
- NCT02683408
- Locations
- ๐บ๐ธ
Sun Valley Arthritis Center, Peoria, Arizona, United States
๐บ๐ธAdvanced Arthritis Care and Research, Scottsdale, Arizona, United States
๐บ๐ธJeffrey Alper, MD, Naples, Florida, United States
Safety and Efficacy of PDL-0101 in Patients With Hyperlipidemias: a Pilot Study.
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- Primus Pharmaceuticals
- Target Recruit Count
- 103
- Registration Number
- NCT02582424